EUCTR2016-003291-47-GB进行中（未招募）1 期
A phase Ib/IIa clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer - POLERISE
niversity Hospital Southampton NHS Trust0 个研究点目标入组 100 人开始时间: 2020年7月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Histologically or cytologically proven castrate resistant prostate cancer
- •2. Metastatic disease. Measurable or evaluable disease is acceptable
- •3. In the dose escalation phase of the trial patients may be enzalutamide naive or refractory by either:
- •i.Commencing enzalutamide for the first time as a treatment for mCRPC as a result of entering this trial
- •ii.Receiving retreatment with enzalutamide as a result of entering this trial providing a minimum of 12 weeks has elapsed since prior enzalutamide. Prior enzalutamide in these circumstances may have been given for either hormone sensitive prostate cancer (for example within the STAMPEDE or ENZAMET clinical trials) or as a conventional treatment for mCRPC. There are no restrictions on other treatments used during this period. Such patients should have tolerated an enzalutamide dose of 160mg once daily
- •In the dose expansion phase of the trial patients will be enzalutamide refractory by either:
- •i.Currently receiving enzalutamide (for a minimum of 12 weeks) and with evidence of PSA and/or radiological progression according to RECIST 1.1 and PCWG3 criteria as judged by the investigator. These patients should have tolerated an enzalutamide dose of 160mg once daily. These patients may continue enzalutamide through the screening period.
- •ii.Have previously had evidence of PSA and/or radiological progression during a minimum of 12 weeks of enzalutamide treatment according to RECIST 1.1 and PCWG3 criteria as judged by the investigator. There are no restrictions on the time period since this prior use of enzalutamide or other treatments used during this period. These patients must have tolerated an enzalutamide dose of 160mg once daily. Where there has been a break of >8 weeks between prior enzalutamide and restarting it in this trial, patients will initially receive a four week run in period of single agent enzalutamide before commencing combination therapy to exclude a PSA response. Patients who exhibit a PSA decrease during the first four weeks will have the option to continue enzalutamide until the point of subsequent disease progression and could then enter the trial to commence combination therapy after discussion with the sponsor.
- •4.Serum testosterone <1.7 nmol/L (< 50 ng/dL)
- •5.No other current therapies for prostate cancer. Allowable exceptions are:
- •i.Use of an LHRH agonist or antagonist where required for ongoing androgen deprivation
- •ii.Ongoing enzalutamide for patients entering the Dose Expansion Phase
- •iii.Denosumab or bisphosphonates such as zoledronate or pamidronate
- •6.ECOG performance status 0 to 2
- •7.Haemoglobin = 8.5 g/dL; platelets = 100 x 109/L; neutrophils = 1.0 x109/L; INR = 1.5
- •8.Bilirubin = ULN; ALT and AST = 1.5 x ULN
- •9.For patients entering the Dose Expansion Phase of the trial: PSA of = 2 ng/mL
- •10.Able to swallow oral trial drugs
- •11.Able to safely provide both an archival formalin fixed paraffin embedded (FFPE) prostate cancer tissue sample and a prostate cancer fresh tissue sample from either the prostate or a metastatic site
- •12.Fertile men must agree to use a highly effective method of birth control while on study drug and up to 3 months after the last dose of study drug (see section 4.7)
- •13.Life expectancy > 3 months
- •14.Aged 16 years or over
- •15.Provision of written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years)
排除标准
- •1.Patients with predominantly small cell or neuroendocrine differentiated prostate cancer
- •2.Administration of an investigational agent, chemotherapy or major surgery within 28 days of first dose of trial medication
- •3.Receiving a known CYP3A4 or CYP2C8 inducer or inhibitor (see appendix) within 2 weeks of starting trial treatment
- •4.Use of systemic corticosteroids within 2 weeks of starting trial treatment (topical and inhaled corticosteroids are acceptable)
- •5.Malabsorption syndrome, previous gastrointestinal surgery or other gastrointestinal condition that may affect drug absorption
- •6.Clinically significant cardiac arrhythmias including bradyarrhythmias and/or patients who require anti-arrhythmic therapy (excluding beta blockers or digoxin)
- •7.Congenital long QT syndrome or patients taking concomitant medications known to prolong the QT interval
- •8.Patients with a prolonged QTc interval >480msec
- •9.History of clinically significant cardiac disease or congestive heart failure > New York Heart Association (NYHA) class 2. Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months
- •10.Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication
- •11.Patients taking warfarin. (Use of low molecular weight heparin is acceptable as an alternative for anticoagulation.)
- •12.For patients entering the Dose Expansion Phase of the trial: Prior malignancy with an estimated = 30% chance of relapse within 2 years in the view of the investigator with the exception of surgically treated basal or squamous cell carcinoma of the skin, melanoma in-situ or non-muscle invasive bladder cancer
- •13.History of seizures or any condition that may predispose to seizure including, but not limited to, underlying brain injury, stroke, primary brain tumours, brain metastases or alcoholism
- •14.History of loss of consciousness within the previous 12 months
- •15.Known brain or leptomeningeal involvement
- •16.Unresolved clinically significant toxicity from prior therapy (except alopecia and grade 1 peripheral neuropathy)
- •17.Inability to comply with trial and follow up procedures
研究者
相似试验
终止
不适用
The study of pexidartinib and enzalutamide as a combined treatment in men with prostate cancer resistant to other treatmentsProstate cancerCancerISRCTN13103155niversity Hospital Southampton NHS Foundation Trust100
已完成
2 期
A Multicenter phase II study of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancerJPRN-UMIN000007386Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine28
暂停
2 期
WT1 peptide pulse dendritic cells vaccine therapy for pancreatic cancer following resectioPancreatic cancerJPRN-jRCTc031190107Yanagisawa Ryu144
已完成
1 期
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid TumorsSolid TumorNCT02718911Eli Lilly and Company72
已完成
1 期
Clinical phase I study of S-1-concurrent carbon ion radiotherapy for squamous cell carcinoma of the nasal cavity and paranasal sinusesSquamous cell carcinoma of the nasal cavity and paranasal sinusesJPRN-UMIN000012135Hyogo Ion Beam Medical Center6